Cancer cell panel profiling of MAPK pathway inhibitors

April 3rd, 2024|

The MAPK signal transduction pathway plays a key role in tumor progression. Mutations in the corresponding driver genes, such as KRAS and BRAF, are oncogenic drivers in several malignancies. Tumors driven by V600-mutated [...]

New bioinformatics service

January 11th, 2024|

Oncolines launches ProteomicsProfiler Figure (A) Scatterplots of basal gene and protein expression levels for EGFR (left, strongly correlated) and KDR (right, not correlated) in cancer cell lines. (B) Boxplot of Pearson correlations [...]

Oncolines presentation at Revvity Symposium Ghent

October 18th, 2023|

Biomarkers for Patient Stratification and Target Engagement Dr. Guido Zaman, Managing Director of Oncolines B.V., will present at the Revvity North Symposium Life Science & Applied Genomics 2023, which will take place [...]

New case study on Oncolines® website

September 1st, 2023|

Target identification of hits from a phenotypic screen Phenotypic screens measure a desired biological effect in a disease-relevant cellular context. In contrast to target-based assays, phenotypic screens are agnostic of a defined molecular [...]

New publication in Cancer Chemotherapy and Pharmacology

July 27th, 2023|

Comparative biochemical kinase profiling of VEGFR2 inhibitors Figure. Radar plot showing residual activity of 270 kinases in the presence of rivoceranib (160 or 1600 nM) or 1000 nM of 10 FDA-approved reference [...]

New Oncolines publication in Cancers

February 8th, 2023|

IL4I1 in ascites as a marker in high-grade serous ovarian cancer The emergence of immunotherapy has revolutionized cancer treatment for various malignancies. However, immunotherapies have demonstrated only limited efficacy in ovarian cancer, [...]

Oncolines Team Joins Symeres

January 10th, 2023|

Symeres acquires Oncolines, further strengthening its drug discovery and biology capabilities Nijmegen, the Netherlands: Symeres, a leading global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), [...]

On-demand webinar on cancer genomics

July 29th, 2022|

Cancer genomics is key to Oncolines’ cancer cell line profiling services and bioinformatics. In PIVOTTalk, a webinar series hosted by the Pivot Park, Jeffrey Kooijman and Tessa de Bitter describe the history [...]

Oncolines News Flash

March 9th, 2022|

First presentation of novel mitotic checkpoint inhibitor BAL0891 data at ESMO TAT congress 2022 At the virtual Targeted Anticancer Therapy (TAT) congress, which was organized by the European Society of Medical Oncology (ESMO) [...]

Oncolines News Flash

March 3rd, 2022|

Oncolines to present detailed profiling of recently approved kinase inhibitors at the ESMO TAT Currently approved small molecule kinase inhibitors act only through a limited number of kinase targets. Well-known targets are EGFR, [...]

Oncolines News Flash

February 4th, 2022|

OncolinesProfiler™ Compound Library is approaching the 200 mark. Clustering analysis via OncolinesProfiler™ compares your compound’s IC50 fingerprint against the cellular activity of other anti-cancer therapeutics. The OncolinesProfiler™ compound library started out as a [...]

Oncolines opens a new screening lab

November 2nd, 2021|

Oncolines is expanding its lab capacity with a new screening lab including cell culture facilities. Oncolines opens a new screening lab Oncolines is expanding its lab [...]

NTRC Precision Medicine Services is now Oncolines

September 28th, 2021|

As an independent company, Oncolines will now be singularly focused on offering the best precision medicine services in oncology and cancer immunotherapy for our clients. Our Oncolines™ cancer cell line panels can identify drug [...]

Case study: Altered drug response in 3D spheroids

May 25th, 2021|

May 25, 2021: A new case study is presented, in which the use of spheroids for the determination of drug sensitivity is highlighted. The figure shows dose-response curves of the KRAS [...]

  • Featured image co-culture assay for paper Grobben et al (2021) Frontiers in Immunology

Tryptophan-metabolizing enzymes in cancer immunology

January 28th, 2021|

January 28, 2021: A new article on the role of tryptophan-metabolizing enzymes in cancer immunology is now online in Frontiers in Immunology (Grobben et al., 2021). The figure shows a co-culture assay of [...]

  • graphic NTRC and Radboud explore new methods to predict chemotherapy response in ovarian cancer

Predictive approach for clinical response to chemotherapy

December 21st, 2020|

December 21: A new article on malignant ascites as a model for drug sensitivity testing is now online in Oncotarget (den Ouden et al, 2020). New in Oncotarget: Chemotherapy sensitivity [...]

  • new website NTRC Therapeutics

New website on small molecules for precision oncology:

December 1st, 2020|

December 01: Read about NTRC Therapeutics translational science platforms and drug discovery projects at New website on small molecules for precision oncology: Oss, December 01, Targeted therapies [...]

  • visual of ASH2020

Presentations at ASH2020

November 30th, 2020|

November 30: Join us at ASH2020 for two oral presentations on December 7th, by Jordy van der Zwet and Valentina Cordo. Combination therapies for T-ALL presented at ASH2020 Oss, [...]

NTRC launches new website:

July 30th, 2020|

July 30, 2020: NTRC launches for biochemical assays in drug discovery. Biochemical assays for determination of binding characteristics Oss, July, 30, 2020 – NTRC Precision Medicine Services proudly [...]

  • logo AACR 2020 virtual meeting. NTRC presents a poster on High TDO and IDO1 expression in ovarian cancer-associated cells isolated from malignant ascites

NTRC Presents at AACR Virtual Annual Meeting II

June 23rd, 2020|

June 23, 2020: NTRC presents the poster #5604, titled 'High TDO and IDO1 expression in ovarian cancer-associated cells isolated from malignant ascites' at the AACR Virtual Annual Meeting II. High [...]

  • NTRC will expand its laboratory space

NTRC Expands its Capacity in Molecular Biology Services

May 4th, 2020|

May 04, 2020: NTRC's new laboratory space for Mechanistic Cell Biology. Additional Laboratory Space for Molecular Biology Services Oss, May, 4th, 2020 – Happy to announce that NTRC is [...]

  • Gene expression in patient material

Expression of Cancer Immunotherapy Targets in Patient Material

March 10th, 2020|

Gene expression of TDO and IDO1 in ovarian cancer cell samples isolated from ascites. Expression of Cancer Immunotherapy Targets in Patient Material Oss, March, 04th, 2020 – ESMO has made [...]

New predictive drug response biomarkers for approved kinase inhibitors

November 1st, 2018|

Oss, November, 02, 2018 –  Kinase inhibitors illustrate the successful translation of basic scientific knowledge of cancer into new targeted therapies. Selecting the right patient population based on the occurrence of specific cancer driver events [...]

NTRC’s key TTK kinase inhibitor patent granted in US

September 25th, 2017|

Oss, September, 19th , 2017 – NTRC, a biopharmaceutical company focused on the discovery and development of innovative precision medicines for the treatment of cancer, today announced that the United States Patent and Trademarks Office [...]

Structural insight into the function of TDO in healthy aging

December 23rd, 2016|

Oss, Groningen, December, 23rd, 2016 – Researchers from the European Research Institute for the Biology of Aging (ERIBA) University of Groningen, the Netherlands) in collaboration with the Netherlands Translational Research Center B.V. have identified an [...]

NTRC launches comparative cancer cell line profiling

September 14th, 2015|

Oss, September, 14th, 2015 – NTRC today announced that it has extended its bioinformatics analysis to its Oncolines™ cancer cell line profiling service. OncolinesProfiler™ involves the comparison of a clients’ compound against more than 100 [...]

NTRC launches assay for mouse IDO1 and mouse TDO activity

January 15th, 2015|

Cancer immunotherapy aims at the stimulation of the body’s immune system to fight cancer. The T-cell immune response against cancer cells is dampened by the activity of the enzymes indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase [...]

NTRC launches Oncolines™ 66 cell line panel

October 1st, 2014|

NTRC has extended its Oncolines™ cancer cell line panel to 66 cancer cell lines. The Oncolines™ panel represents a broad range of tumor tissues and all most frequent genetic changes in human cancer. The previous [...]

NTRC will attend BIO 2014 in San Diego

May 5th, 2014|

Gavin Clark, VP Business Development of NTRC, will attend BIO 2014 Conference held in San Diego from June 21st to June 26th. Gavin Clark will be available to meet with interested parties from pharmaceutical industries [...]

Oncolines™ presented at the European Cancer Congress 2013

September 26th, 2013|

Joost Uitdehaag will present during the European Cancer Congress 2013. The poster entitled 'Drug sensitivity markers for approved kinase inhibitor drugs from cell panel profiling' decribes the recent results obtained after profiling and bioinformatic analysis [...]

NTRC starts at the Life Sciences Park Oss

June 6th, 2012|

Oss – 6 June 2012 - Netherlands Translational Research Center B.V. (NTRC) starts operations at the Life Sciences Park Oss, after successful closing its first round of financing. With the financial support of the Brabant [...]